Orphan Drug Safety: FDA Asks How Much Pre-Approval Data Is Enough?
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology will be asked to weigh pre-approval data requirements and discuss innovative approaches to boosting drug development for rare diseases at its March 2 meeting.
You may also be interested in...
Orphan Drugs Warrant Flexibility On Clinical Pharmacology Data, FDA Panel Says
FDA should use its regulatory flexibility to require fewer pre-approval clinical pharmacology studies, with increased emphasis on post-marketing studies and mandatory registries, to speed development of orphan drugs, the agency’s Advisory Committee for Pharmaceutical Science and Clinical Pharmacology said.
Orphan Drugs Warrant Flexibility On Clinical Pharmacology Data, FDA Panel Says
FDA should use its regulatory flexibility to require fewer pre-approval clinical pharmacology studies, with increased emphasis on post-marketing studies and mandatory registries, to speed development of orphan drugs, the agency’s Advisory Committee for Pharmaceutical Science and Clinical Pharmacology said.
CSL Behring's Corifact Clears FDA On 14-Patient Trial
The orphan drug, for a rare blood disorder, is the latest in a history of drugs for ultra-orphan conditions.